Home Sitemap Contact us Accessibility Statement Top of the page
  • Axsain® (capsaicin cream 0.075%)

    Axsain®

    (capsaicin cream 0.075%)

Prescribing Axsain®

Axsain® (capsaicin cream 0.075%)

Therapeutic indications

Axsain® (capsaicin cream 0.075%) is indicated:

  • For the symptomatic relief of neuralgia associated with and following Herpes Zoster infections (post-herpetic neuralgia) after open skin lesions have healed
  • For the symptomatic management of painful diabetic peripheral polyneuropathy1

Facts about Axsain®

In clinical trials, Axsain® has been shown to be an effective and generally well tolerated analgesic for the relief of neuropathic pain associated with painful PDN adn PHN.2-4

After long-term treatment with Axsain® (up to two years), burning or stinging at the site of application was recorded in only 9% of patients.4

About Axsain®

Pain for healthcare professionals

Axsain® (capsaicin cream 0.075%) is for topical application1

Capsaicin binds to skin-based nociceptors, initially causing localised neurogenic inflammation then cumulatively depleting inflammatory agents including Substance P.1

For the full list of excipients, see Section 6.1 of the Summary of Product Characteristics.



Marketing Authorisation

Cephalon UK Limited
Ridings Point, Whistler Drive
Castleford, West Yorkshire
WF10 5HX
United Kingdom

Marketing Authorisation Number(s)

  • PL 16260/0016

Resources for Axsain®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect
Medicine supporting documentation for Axsain®

1 Axsain® (capsaicin cream 0.075%) Summary of Product Characteristics.

2 Tesfaye S, Selvarajah D. Recent advances in the pharmacological management of painful diabetic neuropathy. S Afr J Diabetes Vasc Dis 2010; 7: 139-142.

3 Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diabetes 2005; 23: 9-15.

4 Watson CP, Tyler KL, Bickers JR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of portherpetic neuralgia. Clin Ther 1993; 15: 510-526.

Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a